| Literature DB >> 31123412 |
Azar Dokht Khosravi1,2, Shahab Taee3, Aram Asarehzadegan Dezfuli1, Hossein Meghdadi2, Fatemeh Shafie2.
Abstract
Background and aim: Currently, the rate of hospital-acquired infections due to drug-resistant Pseudomonas aeruginosa strains shows an increasing trend and remains one of the principal reasons for mortalilty in burn patients. This study aimed to investigate the prevalence of genes conferring resistance to carbapenems in P. aeruginosa isolates from burn patients.Entities:
Keywords: Pseudomonas aeruginosa; antibiotics; carbapenems; drug susceptibility test; encoding genes
Year: 2019 PMID: 31123412 PMCID: PMC6511252 DOI: 10.2147/IDR.S197752
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Sequence of primers used in the present study
| Primer | Sequence | Gene | Product size (base pair) |
|---|---|---|---|
| CGTCTAGTTCTGCTGTCTTG | 798 | ||
| GCGTGGTTAAGGATGAACAC | 438 | ||
| GGTTTGGCGATCTGGTTTTC | 621 | ||
| TATGCAGCTCCTTTAAGGGC | 537 |
Notes: F, forward primer; R, reverse primer.
Figure 1Antibiotic resistance pattern of the 50 clinical P. aeruginosa isolates.
Abbreviations: AK, amikacin; GM, gentamicin; IMP, imipenem; MEM, meropenem; CAZ, ceftazidime; CIP, ciprofloxacin; CPM, cefepime; PTZ, piperacillin-tazobactam; CL, colistin; PIP, piperacillin; ATM, aztreonam.
Figure 2Rate (%) of antimicrobial resistance of MDR and XDR Pseudomonas aeruginosa isolates to antimicrobial agents used in present study.
Abbreviations: AK, amikacin; GM, gentamicin; IMP, imipenem; MEM, meropenem; CAZ, ceftazidime; CIP, ciprofloxacin; CPM, cefepime; PTZ, piperacillin-tazobactam; CL, colistin; PIP, piperacillin; ATM, aztreonam; MDR, multidrug-resistant; XDR, extensively drug resistant.
The distribution of encoding genes among isolates
| Number | Susceptibility patterns | MDR | XDR | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | A | B | B | C | C | D | E | F | G | H | ||||
| GM | AK | IMP | MEM | CAZ | CPM | CIP | PTZ | PIP | ATM | CL | ||||
| 1 | R | R | R | R | R | R | R | S | R | S | S | – | + | BIC |
| 2 | R | R | R | R | R | R | R | R | R | S | S | – | + | NDM |
| 3 | R | R | R | R | R | R | R | R | R | R | S | – | + | – |
| 4 | R | R | R | R | R | R | R | R | R | S | S | – | + | NDM |
| 5 | R | R | R | R | R | R | S | S | R | S | S | + | – | – |
| 6 | R | R | R | R | R | R | S | S | R | S | S | + | – | – |
| 7 | R | R | R | R | R | R | R | S | R | R | S | – | + | NDM |
| 8 | R | R | R | R | R | R | S | S | R | R | S | + | – | NDM |
| 9 | S | R | R | R | R | R | R | R | R | S | S | – | + | – |
| 10 | R | R | R | R | R | R | R | S | S | R | S | + | – | – |
| 11 | S | S | S | S | S | S | S | S | S | S | S | – | – | – |
| 12 | R | R | R | R | R | S | S | S | S | R | S | + | – | – |
| 13 | R | R | R | S | R | R | R | S | R | R | S | – | + | NDM |
| 14 | R | R | S | R | R | R | S | S | R | S | S | + | – | – |
| 15 | R | R | S | S | R | R | S | R | R | R | S | + | – | – |
| 16 | R | R | R | R | R | S | S | S | S | S | S | + | – | – |
| 17 | S | S | R | R | S | S | S | S | S | S | S | – | – | BIC |
| 18 | S | S | S | S | S | S | S | S | S | S | S | – | – | – |
| 19 | R | R | R | R | R | S | S | R | S | R | S | + | – | NDM |
| 20 | R | R | R | R | R | R | S | S | R | S | S | + | – | NDM/BIC |
| 21 | R | R | S | S | R | S | R | S | R | R | S | + | – | – |
| 22 | R | R | S | S | R | R | S | S | R | S | S | + | – | – |
| 23 | S | R | S | S | R | S | R | R | R | R | S | + | – | – |
| 24 | R | R | R | R | R | R | R | R | R | R | S | – | + | OXA |
| 25 | R | R | R | R | R | R | S | S | S | S | S | + | – | – |
| 26 | R | R | R | R | R | R | R | S | R | R | S | – | + | OXA |
| 27 | S | S | R | R | R | S | R | S | R | R | S | + | – | OXA |
| 28 | R | R | R | R | S | R | R | S | S | R | S | + | – | OXA |
| 29 | R | R | R | R | R | R | R | R | R | R | S | – | + | OXA |
| 30 | R | R | S | S | R | R | R | S | S | R | S | + | – | OXA/BIC |
| 31 | R | R | R | R | R | R | R | S | R | R | S | – | + | NDM |
| 32 | S | S | S | S | S | S | S | S | S | S | S | – | – | – |
| 33 | R | R | S | S | R | R | S | S | R | R | S | + | – | – |
| 34 | R | R | R | R | R | R | R | S | R | R | S | – | + | NDM |
| 35 | R | R | S | S | R | S | S | S | S | R | S | + | – | – |
| 36 | R | R | R | R | R | R | R | S | R | R | S | – | + | NDM |
| 37 | R | R | R | R | R | R | R | S | R | R | S | – | + | BIC |
| 38 | R | R | S | S | R | R | S | R | R | S | S | + | – | BIC |
| 39 | R | R | R | R | R | R | R | S | R | R | S | – | + | NDM/BIC |
| 40 | R | R | R | R | R | R | R | R | R | S | S | – | + | – |
| 41 | R | R | R | R | R | R | S | S | S | R | S | + | – | OXA |
| 42 | R | R | R | R | R | R | R | R | R | R | S | – | + | NDM/OXA |
| 43 | R | R | S | S | R | R | S | R | R | R | S | + | – | – |
| 44 | R | R | R | R | R | R | R | S | R | R | S | – | + | – |
| 45 | R | R | R | R | R | S | S | S | R | R | S | + | – | NDM |
| 46 | R | R | S | S | R | R | S | S | S | R | S | + | – | OXA |
| 47 | R | R | R | R | R | R | R | R | R | R | S | – | + | – |
| 48 | S | S | S | S | S | S | S | S | S | S | S | – | – | – |
| 49 | R | R | R | R | R | R | S | R | S | R | S | + | – | NDM |
| 50 | R | R | R | R | R | R | R | S | R | S | – | + | – | |
Notes: Antibiotic classes: A, aminoglycosides; B, carbapenems; C, cephalosporins; D, fluoroquinolones; E, ß-lactamase inhibitors; F, penicillins; G, monobactam; H, lipopeptides.
Abbreviations: AK, amikacin; GM, gentamicin; IMP, imipenem; MEM, meropenem; CAZ, ceftazidime; CIP, ciprofloxacin; CPM, cefepime; PTZ, piperacillin-tazobactam; CL, colistin; PIP, piperacillin; ATM, aztreonam; MDR, multidrug-resistant; XDR, extensively drug resistant, R, resistant; S, susceptible.